Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.32641/andespediatr.v92i4.3825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immobilization of L-Asparaginase on biofunctionalized magnetic graphene oxide nanocomposite: A promising approach for Enhanced Stability and reusability.
Heliyon
November 2024
Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz, Iran.
The application of the amidohydrolase enzyme, L-asparaginase (ASNase), as a biocatalyst in the food and pharmaceutical industries has garnered significant interest. However, challenges such as hypersensitivity reactions, limited stability, and reusability under various operational conditions have hindered its cost-effective utilization. This paper introduces a novel nano-support for ASNase immobilization, namely the nanocomposite of iron oxide magnetic nanoparticles and amino acid-decorated graphene oxide (GO-Asp-FeO).
View Article and Find Full Text PDFImpact of single-nucleotide variants and individual characteristics on adverse events of L-asparaginase in children with acute lymphoblastic leukemia.
Front Pharmacol
October 2024
Faculty of Medicine and Psychology, Autonomous University of Baja California, Tijuana, Mexico.
Introduction: L-Asparaginase (L-Asp) is a key drug in the treatment of acute lymphoblastic leukemia (ALL); however, it is commonly associated with the occurrence of adverse events (AE). Risk factors such as age, sex, nutritional status, and some single nucleotide variants (SNVs) in specific genes could be related to hypersensitivity reactions to L-Asp. The objective of this study was to identify the influence of individual characteristics and three SNVs in the and genes on the occurrence of the most significant adverse events caused by the use of L-Asp in Mexican children with ALL.
View Article and Find Full Text PDFRecombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 study.
Blood Adv
January 2025
Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.
Children's Oncology Group study AALL1931 investigated the efficacy and safety of recombinant Erwinia asparaginase (JZP458) in patients with acute lymphoblastic leukemia/lymphoblastic lymphoma and hypersensitivity reactions/silent inactivation to Escherichia coli-derived asparaginases. Each pegylated Escherichia coli asparaginase dose remaining in a patient's treatment plan was replaced by intramuscular (IM) or IV JZP458 (6 doses) administered Monday/Wednesday/Friday (MWF). Three IM cohorts (1a [25 mg/m2 MWF], n = 33; 1b [37.
View Article and Find Full Text PDFPopulation pharmacokinetics and pharmacodynamics of L-asparaginase and its impact on the development of pancreatitis and hypersensitivity reactions in children with leukemia under treatment.
Drug Chem Toxicol
October 2024
Red Latinoamericana de Implementación y Validación de Guías Clínicas Farmacogenómicas (RELIVAF-CYTED), Santiago, Chile.
L-asparaginase (L-Asp) is an essential enzyme in the treatment of patients with Acute Lymphoblastic Leukemia (ALL), commonly associated with adverse events (AE). Knowing the pharmacokinetic and pharmacodynamic (PK/PD) parameters of L-Asp as well as its relationship with the development of AE is an important strategy in the search to improve the efficacy and safety of the treatment. Seventy-four children with ALL that were being treated with L-Asp, were included.
View Article and Find Full Text PDF[Progress in therapy with L-asparaginase].
Rinsho Ketsueki
October 2024
Department of Pediatrics, Kyoto City Hospital.
L-asparaginase is a key drug in the treatment of acute lymphocytic leukemia/lymphoblastic lymphoma and is currently used in treatment regimens for a wide range of age groups, including children, adolescents, young adults, and older adults. Discontinuation of L-asparaginase leads to worse survival outcomes. Strategies such as appropriate prevention and management of asparaginase-specific adverse events such as hypersensitivity reactions and optimizing administration by therapeutic drug monitoring are important to ensure completion of all asparaginase doses planned in each regimen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!